A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) comprises a group of heterogeneous lymphomas that do not fit any other identified PTCL-subgroup and show poor prognosis. To clarify clinical aspects of Japanese PTCL-NOS patients, the Hokkaido Hematology Study Group conducted a multicente...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2013-08, Vol.98 (2), p.171-178
Main Authors: Torimoto, Yoshihiro, Sato, Kazuya, Ikuta, Katsuya, Hayashi, Toshiaki, Hirayama, Yasuo, Inamura, Junki, Kobayashi, Hajime, Kobayashi, Ryoji, Koda, Kyuhei, Kurosawa, Mitsutoshi, Mori, Akio, Ota, Shuichi, Sakai, Hajime, Shigematsu, Akio, Shindo, Motohiro, Shinzaki, Hitoshi, Takahashi, Fumihiko, Takimoto, Rishu, Tanaka, Junji, Yamamoto, Satoshi, Kohgo, Yutaka, Fukuhara, Takashi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anthracyclines - adverse effects
Asian Continental Ancestry Group
Autografts
Biological and medical sciences
Child
Disease-Free Survival
Female
Follow-Up Studies
Hematologic and hematopoietic diseases
Hematology
Humans
Japan - epidemiology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, T-Cell, Peripheral - mortality
Lymphoma, T-Cell, Peripheral - therapy
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Retrospective Studies
Risk Factors
Stem Cell Transplantation
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) comprises a group of heterogeneous lymphomas that do not fit any other identified PTCL-subgroup and show poor prognosis. To clarify clinical aspects of Japanese PTCL-NOS patients, the Hokkaido Hematology Study Group conducted a multicenter retrospective analysis. The median age of the 107 patients (male 65.4 %) was 67 years. The majority (82.4 %) had stage III/IV disease. Following the international prognostic index, 65.7 % were categorized as high intermediate or high risk. Primary chemotherapy was selected in 96 (90 %) patients, 86 of whom received anthracycline regimens. Sixteen patients received high-dose chemotherapy with autologous stem cell transplantation. Forty-eight (52 %) of the 92 evaluable patients achieved complete remission (CR) or CR/unconfirmed after the primary treatment, in which 22 (46 %) relapsed. The estimated 5-year overall survival (OS) of all patients was 35 %. Three independent risk factors (RFs) associated with OS, bulky disease (hazard ratio HR = 5.324; p  = 0.019), age >60 years (HR = 3.015; p  = 0.025), and platelet count less than 10 × 10 4 /μL (HR = 3.999; p  = 0.036), were identified in a multivariate analysis. Using these three RFs, the OS curves were significantly stratified into three risk groups (low risk, 0 RFs, 3-year-OS 72 %; intermediate risk, one RF, 30 %; high risk, two or three RFs, 0 %; p  = 0.0005). These findings may provide valuable information for the management of Japanese PTCL-NOS patients.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-013-1383-z